Form 4: Humacyte Director Michael Constantino Granted 80,000 Stock Options

Humacyte, Inc. Director Michael T. Constantino was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Summary

• Michael T. Constantino, a Director of Humacyte, Inc. (HUMA), was granted 80,000 stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these stock options is $2.41 per share.
• The options have an expiration date of June 12, 2035.
• The vesting schedule for the options is as follows: the first 25% becomes exercisable on June 12, 2026, and thereafter, 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.
• Following this transaction, Mr. Constantino beneficially owns 80,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a routine compensation event, the grant of stock options aligns the director's interests with shareholder value, which is generally viewed favorably from a corporate governance perspective. There are no negative operational or financial implications directly from this filing.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $2.41 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, as new shares of common stock would be issued.

Risks

• Potential future dilution of existing shares if the granted stock options are exercised.
• The value of the options is contingent on Humacyte's stock price exceeding the $2.41 exercise price, posing a risk to the option holder if the stock underperforms.

Future Outlook

The document details the future vesting schedule of the granted stock options, indicating that the options will become exercisable incrementally over a four-year period, with full vesting by June 12, 2029. The options themselves are valid until June 12, 2035.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a form of long-term incentive compensation designed to align management and director interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a standard practice across various industries, including biotechnology, aligning the director's financial incentives with the company's long-term stock performance.
• The vesting schedule, with a cliff vesting followed by monthly increments over several years, is typical for equity compensation plans, similar to those observed in companies like Gilead Sciences or Amgen for their non-employee directors, ensuring continued commitment.

Related Party Transactions

• This Form 4 reports an equity grant from Humacyte, Inc. to Michael T. Constantino, a Director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned director incentives for long-term stock performance.
• Director (Michael T. Constantino): Receives equity-based compensation, aligning personal financial success with the company's stock performance.

Next Steps

• The stock options will begin to vest on June 12, 2026, with subsequent monthly vesting until June 12, 2029.
• The director may choose to exercise the vested options at any time before their expiration on June 12, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Humacyte, HUMA, Stock Options, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Vesting Schedule